Skip to main content

Dalfampridine Pregnancy and Breastfeeding Warnings

Medically reviewed by Last updated on Sep 22, 2021.

Dalfampridine is also known as: Ampyra

Dalfampridine Pregnancy Warnings

Use is not recommended.

AU TGA pregnancy category: C
US FDA pregnancy category: C

-Adequate methods of contraception should be encouraged.
-If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.

Animal studies have revealed reproductive toxicity. There are no controlled data in human pregnancy. It is not known whether this drug can cause fetal harm or adversely affect reproductive capacity in humans.

AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Dalfampridine Breastfeeding Warnings

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: Because this drug is highly lipophilic, it may be excreted into human milk.

See references

References for pregnancy information

  1. "Product Information. Ampyra (dalfampridine)." Acorda Therapeutics (2010):

References for breastfeeding information

  1. "Product Information. Ampyra (dalfampridine)." Acorda Therapeutics (2010):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.